Beckman Coulter introduces IOTestR CD136 (RON)-PE conjugated monoclonal antibody for the identification of a receptor protein kinase potentially involved in tumour development and growth
The CD136 antigen is the product of the recepteur d'origine nantais (RON) gene.
It is mainly expressed on cells of epithelial origin.
The RON receptor belongs to a group of kinases that play important regulatory roles in normal tissue and can also be involved in cellular disorganization and alteration when overexpressed or mutated.
The new CD136 (RON) antibody from Beckman Coulter will be valuable in a range of basic and clinical research, and has been used in a number of recent and current cancer studies.
It will also be useful in pharmaceutical research on therapies designed to block the tumorigenic process.
The preformulated, standardised IOTest CD136 (RON)-PE monoclonal antibody is provided in 100-test vials and is the only directly conjugated monoclonal antibody on the market.
It can be used to assess RON expression on both normal and abnormal epithelial cells, recognizing proRON and RON, and the three known RON variants.
"This antigen marker is very important for the study of epithelial tumours," commented Michel Pagniez, cellular analysis product manager for Beckman Coulter.
"The successful blocking of this kinase could result in efficient cancer therapies".
CD136 (RON)-PE is approved for research use only.
